Medtronic EPS (Diluted) decreased by 16.8% to $0.89 in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 11.9%, from $1.01 to $0.89. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 7.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.00 | $0.56 | $0.97 | $1.10 | $1.10 | $0.70 | $0.32 | $0.92 | $0.88 | $0.59 | $0.68 | $0.99 | $0.50 | $0.80 | $0.99 | $1.01 | $0.81 | $0.81 | $1.07 | $0.89 |
| QoQ Change | — | -44.0% | +73.2% | +13.4% | +0.0% | -36.4% | -54.3% | +187.5% | -4.3% | -33.0% | +15.3% | +45.6% | -49.5% | +60.0% | +23.7% | +2.0% | -19.8% | +0.0% | +32.1% | -16.8% |
| YoY Change | — | — | — | — | +10.0% | +25.0% | -67.0% | -16.4% | -20.0% | -15.7% | +112.5% | +7.6% | -43.2% | +35.6% | +45.6% | +2.0% | +62.0% | +1.3% | +8.1% | -11.9% |